An Update on Anemia Management in Chronic Kidney Disease
Author Information
Author(s): Geoffrey Teehan, Robert L. Benz
Primary Institution: Lankenau Medical Center
Hypothesis
What is the optimal hemoglobin level for treating anemia in patients with chronic kidney disease?
Conclusion
Normalizing hemoglobin levels in patients with chronic kidney disease does not provide clear benefits and may even pose risks.
Supporting Evidence
- CHOIR trial showed higher death rates in patients with higher hemoglobin levels.
- CREATE trial found no significant cardiovascular benefits from higher hemoglobin targets.
- TREAT trial indicated increased stroke risk with higher hemoglobin levels.
Takeaway
Doctors are trying to find the best hemoglobin level for people with kidney problems, but making it too high can be dangerous.
Methodology
The review analyzes three recent randomized trials (CHOIR, CREATE, TREAT) on anemia management in chronic kidney disease.
Potential Biases
Potential bias due to the open-label design of some trials and the exclusion of certain patient groups.
Limitations
The trials had varying sample sizes and patient demographics, which may affect the generalizability of the results.
Participant Demographics
Patients with chronic kidney disease stages III-IV, including those with diabetes.
Statistical Information
P-Value
P = .03
Confidence Interval
95% C.I. 1.03–1.74
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website